Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Double-Expressor Diffuse Large B-Cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive double-expressor diffuse large B-cell lymphoma.
Epistemonikos ID: 44e42949830dabadf5f54a65cb98ee6865774371
First added on: Jul 23, 2025